As we celebrate International Women's Day today, Kiran Mazumdar-Shaw says determination and confidence helped her to build Biocon.
In an interview to CNBC-TV18, Shaw, chairperson and managing director, said, "The message I want to give women is that a purposeful determined focus on anything that they endeavour to do is something that women should feel confident of achieving.
Shaw said Biocon has just launched biosimilar Trastuzumab and insulin Glargine in Europe, and hope to launch Pegfilgrastim in European Union soon. However, Glargine and Trastuzumab will be launched in the US this year.
Going forward, Biocon plans to unlock value in the biologics business, but will decide on the right time to do so, Shaw said, "In the interim, the company would build value in the biosimilar business."
Christiane Hamacher, chief executive officer, Biocon Biologics, said she was very glad to join Biocon as the company’s vision is based on a fantastic global portfolio for biosimilars, one of the largest in the world and want to make difference for patients globally and reduce the cost of healthcare.
Giving a special message to women, Hamacher said, "Love what you do and be yourself."
"There would be many opportunities for the future to evolve and make Biocon Biologics a recognised global player in the space," she added.